Aurinia Pharmaceuticals to Acquire Kezar Life Sciences (KZR) for $6.955 Plus CVR

Deal Overview

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), through its subsidiary Aurinia Pharma U.S., announced on March 30, 2026, that it will acquire Kezar Life Sciences, Inc. (NASDAQ: KZR) in a cash-plus-CVR deal. Kezar is a clinical-stage biotech developing zetomipzomib, a first-in-class immunoproteasome inhibitor for autoimmune hepatitis. The deal values Kezar at roughly $51 million on the cash component alone.

Only a preliminary communication filing (SC 14D-9C) has been made so far. The formal offer documents have not been filed. If you own KZR shares, there is nothing to do yet.

Key Terms

Detail	Value
Cash Consideration	$6.955 per share
CVR	One non-transferable CVR per share
Offer Commencement Deadline	April 13, 2026
Expected Closing	Q2 2026
Minimum Tender Condition	Majority of outstanding shares
Closing Net Cash Condition	Kezar must have net cash above $50 million
Merger Structure	Section 251(h) short-form merger (no shareholder vote)
Shareholder Support	Tang Capital Partners (~9.0% holder) committed to tender
Basic Shares Outstanding	7,371,527 (as of March 23, 2026)

The CVR: What You Might Get Beyond $6.955

The CVR is the most important part of this deal for shareholders, and it is also the most uncertain. Each CVR entitles the holder to potential future cash payments from three sources. The excess cash bucket is the only one with a near-term, quantifiable payout. The partnership buckets, as we will show, are conservatively worth zero.

1. Excess Net Cash Above $50 Million

CVR holders receive 100% of Kezar's Closing Net Cash in excess of $50 million, minus certain post-closing CVR-related expenses. This sounds straightforward, but "Closing Net Cash" is not simply cash minus liabilities. The Merger Agreement deducts all liabilities, unpaid transaction expenses (TD Cowen banking fees, Cooley LLP legal costs), D&O tail insurance, change-of-control severance for remaining employees, post-closing wind-down costs, and parent transaction expenses (capped at $250K). No competitor analysis has published this math, so let's walk through it.

How Much Excess Cash Might You Actually Get?

Kezar's 10-K filed March 27, 2026 shows gross cash of $71.88M as of December 31, 2025, with total liabilities of $6.57M. Oxford Finance debt was fully repaid in Q4 2025. A naive calculation would suggest $65.31M in net cash and a $15.31M excess above the $50M threshold, or roughly $2.04 per share. That number is wrong.

The Signing Net Cash was set at exactly $50M. This is the strongest signal in the deal. Both parties, with full access to Kezar's books, agreed that after deducting all liabilities, transaction expenses, tail insurance, severance, and wind-down costs, approximately $50M remained as of the agreement date. That implies roughly $22M in total deductions from the $71.88M gross cash figure, not just the $6.57M in balance sheet liabilities.

Post-Restructuring Burn Rate

Kezar executed a 70% workforce reduction in November 2025, cutting to roughly 9 employees. Q4 2025 GAAP operating expenses excluding restructuring charges were $8.33M ($5.08M R&D plus $3.25M G&A), but that quarter included $1.63M in stock-based compensation. Cash operating expenses were approximately $6.70M for the quarter. However, Q4 was a mixed quarter: one month at the pre-restructuring run rate and two months post-restructuring.

Going forward with 9 employees in wind-down mode, quarterly cash burn is likely $4-6M. Interest income on the remaining cash balance partially offsets this at roughly $0.5-0.7M per quarter. Every month between signing and closing erodes the excess cash cushion further.

Inflows Before Close

Two modest items work in the other direction. Kezar received $800K at the closing of its Sec61 program sale to Enodia Therapeutics on March 6, 2026, with an additional $200K due within 45 days. Interest income on the cash balance continues to accrue. These help but do not materially change the picture.

Excess Cash Scenarios

Total CVR recipients include approximately 7.49M shares: 7.37M basic shares plus roughly 123K in-the-money options (recently granted at a $6.36 strike). Nearly all of Kezar's 1.65M options outstanding are underwater at a weighted average strike of $17.29 and will be cancelled for nothing at close.

Scenario	Closing Net Cash	Excess Above $50M	Per Share (~7.49M)
Deal risk (Aurinia walks)	<$50M	$0	$0
Tight close	~$50M	~$0	~$0
Modest excess	~$53-55M	$3-5M	~$0.40-$0.67
Best case	~$57M+	$7M+	~$0.93+

The realistic range for the excess cash CVR is $0 to roughly $0.67 per share. The best case requires transaction costs and burn to come in well below the implied $22M deduction figure, which is possible but not the base case.

2. Zetomipzomib Development or Disposition

Payments tied to the ongoing development or eventual sale of zetomipzomib, Kezar's lead drug. The drug showed promising Phase 2a results in the PORTOLA trial for autoimmune hepatitis, with 36% of treated patients achieving complete biochemical response versus 0% on placebo. However, four patient deaths in a separate lupus nephritis trial led to FDA clinical holds in 2024. The AIH hold was lifted in May 2025, but the lupus program was discontinued. CVR payments from this bucket depend on Aurinia successfully advancing or monetizing zetomipzomib, which is far from guaranteed.

A critical wrinkle: Kezar owes Onyx Pharmaceuticals (an Amgen subsidiary) up to $167.5M in development, regulatory, and sales milestones under a June 2015 license agreement, plus mid-to-high single-digit royalties on net sales continuing until at least 2034. Onyx also retains a right of first negotiation for any licensed product. If zetomipzomib somehow reaches commercialization, these obligations substantially reduce what flows through to CVR holders. This offset is missing from every other analysis we have seen.

3. Existing Partnership Proceeds: Everest and Enodia

The CVR captures certain proceeds from Kezar's collaboration with Everest Medicines and the Enodia Therapeutics Sec61 sale. These buckets look attractive on paper. In practice, both are worth approximately zero.

Everest Medicines: PALIZADE Is Dead

Kezar licensed Greater China/Asia-Pacific rights for zetomipzomib to Everest Medicines in 2021, with up to $393M in potential milestones. The PALIZADE Phase 2 trial in lupus nephritis, run by Everest, was suspended in October 2024 after four patient deaths in the Philippines and Argentina. The FDA placed a clinical hold on the lupus nephritis indication that remains in effect.

More telling than the clinical hold is what Everest has done since. Under the collaboration agreement, Everest has a convenience termination right it can exercise at any time following the PALIZADE termination. Zetomipzomib has disappeared entirely from Everest's pipeline communications — it was not mentioned in the company's H1 2025 interim results or FY2024 annual report. Everest is now focused on NEFECON, XERAVA, VELSIPITY, its mRNA platform, and civorebrutinib (a BTK inhibitor) for lupus nephritis — a direct competitor to the indication zetomipzomib was being tested in.

Even without formal termination, no milestones are achievable without restarting a clinical trial from scratch, which would take years and carry serious safety overhang from the patient deaths. Conservative value of the Everest CVR bucket: $0.

Enodia Therapeutics: Years From Any Milestone

Kezar sold its Sec61 discovery program to Enodia Therapeutics for $1M upfront ($800K at close plus $200K within 45 days), received pre-Aurinia-closing. That $1M flows into Kezar's cash balance and gets captured by the Excess Net Cash CVR bucket, not the Enodia Proceeds bucket. The Enodia CVR bucket captures future milestones and royalties tied to commercialization of the program.

Enodia raised a EUR 20.7M (~$25M) seed round in January 2026 from Elaia, Pfizer Ventures, and Bpifrance. They are working toward preclinical candidate selection — not even at the candidate stage yet. IND-enabling studies, IND filing, and Phase 1/2/3 trials all lie ahead, representing at least 8 to 12 years of development before any commercialization milestone. Early development milestones like IND filing or first patient dosed might generate low single-digit millions, but are unlikely within 3 years. Conservative value of the Enodia CVR bucket in any actionable time horizon: $0.

Putting It All Together: What Is the CVR Actually Worth?

With the partnership buckets dissected, here is a conservative valuation of each CVR component:

CVR Component	Conservative Estimate	Per Share (~7.49M)
Excess Net Cash (above $50M)	$0-$5M	$0.00-$0.67
Everest Collaboration Proceeds	~$0	$0.00
Enodia Proceeds	~$0	$0.00
Zetomipzomib Disposition	$0-$5M (speculative)	$0.00-$0.67
Less: Onyx obligations	Offsets any zetomipzomib upside	—
Total Conservative CVR Value	$0-$5M	$0.00-$0.67

The excess net cash is the only near-certain component, and even that depends on closing timing and transaction costs. The partnership buckets are worth approximately zero on any reasonable near-term basis. The zetomipzomib disposition bucket has some speculative value, but the Onyx milestone obligations ($167.5M) and royalties act as a significant offset to whatever deal economics Aurinia might negotiate with a future partner or acquirer.

The CVR has a 10-year term, so there is long-tail optionality if zetomipzomib eventually succeeds. But the CVRs are non-transferable — you cannot sell them on any exchange or secondary market. Once you receive a CVR, you are locked in until milestones pay out or the term expires. If you want full liquidity, your window is before the tender offer closes.

Why KZR Trades Above the Cash Price

KZR shares last traded at $7.39, which is $0.435 (6.3%) above the $6.955 cash component. The stock's 52-week range is $3.59 to $7.45. That $0.44/share gap represents what the market assigns to the CVR, despite it being non-transferable and speculative.

Our conservative estimate puts the total CVR at $0 to $0.67/share, meaning the market is priced within range but toward the optimistic end. The $0.44 implied CVR value is essentially a bet that the excess net cash bucket pays something — which it likely will, but modestly. Jefferies, the only sell-side analyst to issue a note post-deal, set a $7.00 price target, implying near-zero CVR value. Meanwhile, Kezar's book value is $9.58/share and net cash per share is $9.51/share, both well above the $6.955 cash offer.

Two law firms (Ademi LLP and Halper Sadeh LLC) are investigating whether the deal price is fair, which adds a small tailwind for shareholders even if these investigations rarely result in material price improvements.

The $50M Closing Condition: A Real Risk Nobody Is Flagging

The Merger Agreement includes a condition that Kezar's Closing Net Cash must be at or above $50 million. If it falls below that threshold, Aurinia has a 5-business-day window to walk away from the deal. This is not a theoretical risk.

The Signing Net Cash was set at exactly $50M with zero cushion. Every month of burn, every dollar of transaction costs, and every unexpected expense pushes the number closer to or below the line. With quarterly cash burn of $4-6M and potentially significant one-time closing costs still ahead, the math is tight.

The mitigating factor is that Aurinia wants zetomipzomib. If the shortfall is small, Aurinia would likely waive the condition rather than lose the asset. But a large shortfall could give Aurinia genuine leverage to renegotiate or walk. Investors should monitor Kezar's April 3, 2026 earnings call closely for updated cash position guidance.

Share Count and CVR Recipient Math

Basic shares outstanding as of March 23, 2026: 7,371,527. Kezar has approximately 1.65M options outstanding at a weighted average strike of $17.29, nearly all of which are deeply underwater at the $6.955 cash offer price. Only about 123K options are in the money, recently granted at a $6.36 strike. There are essentially no RSUs, warrants, or convertible securities outstanding.

At closing, out-of-the-money options are cancelled for nothing. In-the-money option holders receive the difference between $6.955 and their strike price in cash, plus one CVR per underlying share. Total CVR recipients therefore come to approximately 7.49M (7.37M shares plus 123K in-the-money options).

Timeline and Status

Risks to the Deal

The $50M Closing Net Cash condition is the primary mechanical risk to this deal. As discussed above, the threshold was set with no margin of safety, and ongoing burn plus transaction costs make it a live issue, not a formality.

The CVR's largest potential payout depends on zetomipzomib's future, but the Onyx obligations create a drag that most investors are not aware of. Even if Aurinia successfully advances the drug or sells the rights, up to $167.5M in milestones plus ongoing royalties flow to Onyx before CVR holders see meaningful returns from that bucket. The partnership buckets (Everest and Enodia) are effectively dead money for the foreseeable future.

No formal offer documents have been filed yet. Until the Schedule TO and Schedule 14D-9 are published, we do not have the full CVR Agreement, the exact expiration date, or other critical terms. At $7.39, buying KZR today means paying more than the guaranteed cash and betting on the CVR — specifically, betting that the excess cash bucket delivers. If the deal breaks, the downside is significant given KZR's 52-week low of $3.59.

What No One Else Is Covering

Competitive coverage of this deal is exclusively press-release regurgitation. No analyst or financial blog has published the excess cash CVR math, the Onyx obligation offset, or the partnership bucket analysis. The naive "cash minus liabilities" calculation overstates the likely excess cash payout by 3-4x because it ignores the $22M in implied deductions that both parties agreed to when they set Signing Net Cash at $50M. If you have seen a $2/share excess cash estimate elsewhere, it is almost certainly wrong.

We will update this post when the formal tender offer launches, after the April 3 earnings call, and when the full CVR Agreement becomes available.

---

This post is for informational purposes only and does not constitute investment advice. All information is sourced from SEC filings, the BusinessWire announcement, and public company disclosures.